According to MarketsandMarkets™, the Vascular Access Device Market is projected to grow from about USD 6.27 billion in 2026 to USD 8.68 ...

FDA priority review seeks marstacimab label expansion to ≥6 years with inhibitors and ages 6–11 without inhibitors, addressing populations with limited efficacy from factor replacement and high unmet ...

Nine-year follow-up of gene therapy in haemophilia B confirms long-term safety and reduced bleeding, though full capsid ...

According to MarketsandMarkets, the Vascular Access Device Market is projected to grow from about USD 6.27 billion in 2026 to USD 8.68 billion ...

In the second of a series, columnist Joe MacDonald shares how much his sons benefited from learning to administer infusions ...

Walker, the Super Bowl MVP, was the more explosive of Seattle’s two backs, but had a 34% rushing success rate during the ...

Rutgers hasn't given Steve Pikiell the resources the program needs, but throwing money at his problems is a failing strategy ...

Ferric citrate significantly improves hemoglobin levels and is well tolerated in patients with NDD CKD and iron deficiency anemia.

US FDA grants priority review status to Pfizer’s Hympavzi sBLA to treat two haemophilia A or B patient populations with significant medical need: New York Monday, February 9, 20 ...

The 2025 Season Is In The Rearview Mirror, But Before We Turn The Page, Here Are 10 Positives For The Chicago Bears from ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA ® (pembrolizumab) plus Padcev ® (enfortumab vedotin-ejfv) significantly improved ...